摘要
目的探索分析针对手足口病患儿予以重组人干扰素α1b治疗的临床效果。方法将2018年6月至2019年6月本院收治的200例手足口病患儿作为研究对象并随机分为研究组和对照组,各100例。对照组予以热毒宁注射液静脉滴注联合利巴韦林抗病毒治疗,研究组则予以热毒宁注射液静脉滴注联合重组人干扰素α1b雾化治疗。对比两组临床效果。结果两组治疗后,研究组患儿总有效率(100.00%)显著高于对照组(75.00%),差异显著(P<0.05)。研究组患儿的退热时间、口腔疱疹以及手足皮疹症状消失时间、住院时间显著性短于对照组(P<0.05)。两组治疗前疾病症状积分以及体温监测值无显著差异(P>0.05);治疗后两项指标均显著降低,且研究组显著优于对照组(P<0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05),且均未影响治疗效果。结论针对手足口病患儿予以重组人干扰素α1b实施治疗,可有效改善患儿病情,促进临床症状消失,缩短治疗时间,改善预后,且安全性较高。
Objective To analyze the clinical effect of recombinant human interferon-α1b(RHIFN-α1b)on children with hand-foot-mouth disease(HFMD).Methods From June 2018 to June 2019,200 children with hand-foot-mouth disease were randomly divided into study group and control group,100 cases each.The control group was treated with retuning injection combined with ribavirin,while the study group was treated with retuning injection combined with recombinant human interferonα1b.The clinical effects of the two groups were compared.Results After treatment,the total effective rate(100.00%)of the study group was significantly higher than that of the control group(75.00%),the difference was significant(P<0.05).The antipyretic time,oral herpes,hand and foot skin rash symptom disappearance time and hospitalization time of study group were significantly shorter than that of control group(P<0.05).There was no significant difference between the two groups in the scores of disease symptom and temperature before treatment(P>0.05),and the two indexes decreased significantly after treatment,and the study group was significantly better than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Using recombinant human interferon-α1b to treat children with hand-foot-mouth disease can effectively improve the condition of children,promote the disappearance of clinical symptoms,shorten the treatment time,improve the prognosis,and have higher safety.
作者
陈洁婉
CHEN Jiewan(Pediatrics,Guangxi Tiandong County People's Hospital,Baise Guangxi 531500,China)
出处
《临床研究》
2020年第12期36-38,共3页
Clinical Research
关键词
重组人干扰素Α1B
联用治疗
小儿手足口病
recombinant human interferon-α1b
combined therapy
hand-foot-mouth disease in children
